Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials

Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Digestive and Liver Disease - Volume 49, Issue 8, August 2017, Pages 943-944

Andrea Casadei Gardini, Giovanni Luca Frassineti, Francesco Giuseppe Foschi, Giorgio Ercolani, Paola Ulivi,